Q3 2024 Results - 1 - Q3 2024 Results November 7, 2024 Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, the Spanish Securities Market and Inv ...

On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.This decision follows the company’s November 19 statement rejecting Brookfield’s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share.Canadian fund Brookfield said it had dropped its plan to take over Spain’s Grifols due to a disagreement over the pharmaceutical company’s value, while Grifols said it concurred with the deci ...

Shares of Grifols (GRFS) lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a common ground over the company's value. Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion). Per management, the valuation “significantly undervalues the company’s fundamental prospects and its long-term potential.” ...

Shares of Grifols (GRFS) lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion).Per a regulatory filing submitted to the SEC, Grifols stated that the valuation offered by Brookfield “significantly undervalues the company’s fundamental prospects and its long-term potential.”Brookfield, along with key shareholders of Grifols, had expressed its intent for a potential t ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of GRFS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advic ...

Shares of Grifols (GRFS) rose nearly 7% on Aug 21 following a report issued by Bloomberg, which stated that Canada-based Brookfield Asset Management is in talks with banks to raise funds worth €9.5 billion ($10.6 billion) in debt for its potential acquisition. Through these funds, Brookfield intends to refinance Grifols' existing debt, which includes loans and high-yield bonds. While most of the funding will be in dollars, the participating banks would be requested to commit to providing the funds 'before s ...

Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body's natural immune response SAN CARLOS, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to in ...

Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly Increasing adoption of XEMBIFY is part of Grifols' broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market and whose growth is expected to outpace other indications XEMBIFY becomes the first 20% SCIg with this extended label, allowing patients to begin SCIg therapy without ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adopt ...

Brookfield and family member shareholders of Grifols are in talks to take the Spanish pharmaceutical firm private. The potential buyers asked the board for information so they could do due diligence. Both sides say no agreement has been reached. Brookfield noted that at this time, no deal has been reached, and there's no guarantee that it and the other shareholders will make an offer. Grifols ADRs, which jumped more than 19% yesterday, added a further 0.8% to $8.48 as of 11:18 a.m. ET Tuesday. Despite the t ...